{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:22:57Z","timestamp":1790256177403,"version":"4.1.0"},"reference-count":92,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>US primary care practitioners (PCPs) are the largest clinical workforce, but few provide addiction care. Primary care is a practical place to expand addiction services, including buprenorphine and harm reduction kits, yet the clinical outcomes and health care sector costs are unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the long-term clinical outcomes, costs, and cost-effectiveness of integrated buprenorphine and harm reduction kits in primary care for people who inject opioids.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this modeling study, the Reducing Infections Related to Drug Use Cost-Effectiveness (REDUCE) microsimulation model, which tracks serious injection-related infections, overdose, hospitalization, and death, was used to examine the following treatment strategies: (1) PCP services with external referral to addiction care (status quo), (2) PCP services plus onsite buprenorphine prescribing with referral to offsite harm reduction kits (BUP), and (3) PCP services plus onsite buprenorphine prescribing and harm reduction kits (BUP plus HR). Model inputs were derived from clinical trials and observational cohorts, and costs were discounted annually at 3%. The cost-effectiveness was evaluated over a lifetime from the modified health care sector perspective, and sensitivity analyses were performed to address uncertainty. Model simulation began January 1, 2021, and ran for the entire lifetime of the cohort.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Life-years (LYs), hospitalizations, mortality from sequelae (overdose, severe skin and soft tissue infections, and endocarditis), costs, and incremental cost-effectiveness ratios (ICERs).<\/jats:p><\/jats:sec>Results<\/jats:title>The simulated cohort included 2.25 million people and reflected the age and gender of US persons who inject opioids. Status quo resulted in 6.56 discounted LYs at a discounted cost of $203\u202f500 per person (95% credible interval, $203\u202f000-$222\u202f000). Each strategy extended discounted life expectancy: BUP by 0.16 years and BUP plus HR by 0.17 years. Compared with status quo, BUP plus HR reduced sequelae-related mortality by 33%. The mean discounted lifetime cost per person of BUP and BUP plus HR were more than that of the status quo strategy. The dominating strategy was BUP plus HR. Compared with status quo, BUP plus HR was cost-effective (ICER, $34\u202f400 per LY). During a 5-year time horizon, BUP plus HR cost an individual PCP practice approximately $13\u202f000.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This modeling study of integrated addiction service in primary care found improved clinical outcomes and modestly increased costs. The integration of addiction service into primary care practices should be a health care system priority.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.7888","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:05:21Z","timestamp":1681311921000},"page":"e237888","source":"Crossref","is-referenced-by-count":25,"title":["Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics"],"prefix":"10.1001","volume":"6","author":[{"given":"Raagini","family":"Jawa","sequence":"first","affiliation":[{"name":"Section of General Internal Medicine, Center for Research on Healthcare, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yjuliana","family":"Tin","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Nall","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Calcaterra","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Savinkina","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Marks","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, School of Medicine, Washington University in St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon D.","family":"Kimmel","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"},{"name":"Section of General Internal Medicine, Boston Medical Center, Boston, Massachusetts"},{"name":"Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"},{"name":"Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Barocas","sequence":"additional","affiliation":[{"name":"Divisions of General Internal Medicine and Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"zoi230256r1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugalcdep.2016.04.009","article-title":"Nationwide increase in hospitalizations for heroin-related soft tissue infections: associations with structural market conditions.","volume":"163","author":"Ciccarone","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi230256r2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7326\/M18-2124","article-title":"Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data.","volume":"170","author":"Schranz","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi230256r4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.7326\/M19-3975","article-title":"Medication for opioid use disorder: a national survey of primary care physicians.","volume":"173","author":"McGinty","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi230256r5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","article-title":"Integrating buprenorphine treatment into office-based practice: a qualitative study.","volume":"24","author":"Barry","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi230256r6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine.","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Ann Fam Med"},{"issue":"6","key":"zoi230256r7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","article-title":"Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others.","volume":"39","author":"Olfson","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"zoi230256r8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.7326\/M19-2403","article-title":"Growth and distribution of buprenorphine-waivered providers in the United States, 2007-2017.","volume":"172","author":"McBain","year":"2020","journal-title":"Ann Intern Med"},{"issue":"9","key":"zoi230256r9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.","volume":"23","author":"Walley","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi230256r10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","article-title":"Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review.","volume":"20","author":"Louie","year":"2019","journal-title":"BMC Fam Pract"},{"issue":"12","key":"zoi230256r11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jama.2021.0958","article-title":"Removing one barrier to opioid use disorder treatment: is it enough?","volume":"325","author":"Weimer","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"zoi230256r12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.mcna.2018.02.007","article-title":"Office-based addiction treatment in primary care: approaches that work.","volume":"102","author":"Edelman","year":"2018","journal-title":"Med Clin North Am"},{"issue":"10","key":"zoi230256r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: what actually works? a systematic review.","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"zoi230256r14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.disamonth.2018.12.002","article-title":"The value of harm reduction for injection drug use: a clinical and public health ethics analysis.","volume":"65","author":"Vearrier","year":"2019","journal-title":"Dis Mon"},{"issue":"1","key":"zoi230256r15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12954-022-00594-9","article-title":"Meeting people where they are: implementing hospital-based substance use harm reduction.","volume":"19","author":"Perera","year":"2022","journal-title":"Harm Reduct J"},{"issue":"11","key":"zoi230256r19","doi-asserted-by":"publisher","first-page":"e3661","DOI":"10.1093\/cid\/ciaa1346","article-title":"Long-term infective endocarditis mortality associated with injection opioid use in the United States: a modeling study.","volume":"73","author":"Barocas","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi230256r20","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1016\/S2468-2667(21)00248-6","article-title":"Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study.","volume":"7","author":"Barocas","year":"2022","journal-title":"Lancet Public Health"},{"issue":"2","key":"zoi230256r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0541","article-title":"Simulated cost-effectiveness and long-term clinical outcomes of addiction care and antibiotic therapy strategies for patients with injection drug use\u2013associated infective endocarditis.","volume":"5","author":"Adams","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230256r22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1017\/S0950268814000284","article-title":"Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England.","volume":"143","author":"Hope","year":"2015","journal-title":"Epidemiol Infect"},{"issue":"2","key":"zoi230256r23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/07853890.2016.1235282","article-title":"Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis.","volume":"49","author":"N\u2019Guyen","year":"2017","journal-title":"Ann Med"},{"issue":"1","key":"zoi230256r24","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1186\/s12913-019-4670-4","article-title":"Making the business case for an addiction medicine consult service: a qualitative analysis.","volume":"19","author":"Priest","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"zoi230256r25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMp2204687","article-title":"Hospital standards of care for people with substance use disorder.","volume":"387","author":"Englander","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi230256r27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.09.017","article-title":"Linking patients with buprenorphine treatment in primary care: predictors of engagement.","volume":"181","author":"Simon","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi230256r28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097596","article-title":"Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections.","volume":"9","author":"Lansky","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"zoi230256r29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamapsychiatry.2017.0113","article-title":"Changes in US lifetime heroin use and heroin use disorder: prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"74","author":"Martins","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi230256r30","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"zoi230256r33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.epidem.2018.01.002","article-title":"A Bayesian evidence synthesis approach to estimate disease prevalence in hard-to-reach populations: hepatitis C in New York City.","volume":"23","author":"Tan","year":"2018","journal-title":"Epidemics"},{"key":"zoi230256r34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drugpo.2019.08.006","article-title":"Recent fentanyl use among people who inject drugs: results from a rapid assessment in Baltimore, Maryland.","volume":"74","author":"Buresh","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"12","key":"zoi230256r35","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/infdis\/jit520","article-title":"\u201cTo share or not to share?\u201d serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants.","volume":"208","author":"Smith","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"zoi230256r36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/jiz142","article-title":"Age-related differences in past or present hepatitis C virus infection among people who inject drugs: national human immunodeficiency virus behavioral surveillance, 8 US cities, 2015.","volume":"220","author":"Abara","year":"2019","journal-title":"J Infect Dis"},{"issue":"12","key":"zoi230256r37","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.drugpo.2015.08.013","article-title":"Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.","volume":"26","author":"Kim","year":"2015","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi230256r38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/JNC.0000000000000016","article-title":"Association of self-reported abscess with high-risk injection-related behaviors among young persons who inject drugs.","volume":"30","author":"Asher","year":"2019","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"1-3","key":"zoi230256r39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drugalcdep.2010.11.025","article-title":"Correlates of risky injection practices among past-year injection drug users among the US general population.","volume":"116","author":"Ropelewski","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"zoi230256r43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.drugalcdep.2015.11.011","article-title":"Health behaviors of young adult heroin injectors in the Seattle area.","volume":"158","author":"Cedarbaum","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi230256r44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0376-8716(94)01060-X","article-title":"Cocaine use and risky injection and sexual behaviors.","volume":"37","author":"Hudgins","year":"1995","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi230256r45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000312","article-title":"High mortality among patients with opioid use disorder in a large healthcare system.","volume":"11","author":"Hser","year":"2017","journal-title":"J Addict Med"},{"key":"zoi230256r49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.02.024","article-title":"Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs.","volume":"162","author":"Caudarella","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi230256r50","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/1469-0691.12395","article-title":"Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis\u2014prospective cohort study.","volume":"20","author":"Alagna","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"zoi230256r51","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/cid\/ciy632","article-title":"Many opportunities to record, diagnose, or treat injection drug-related infections are missed: a population-based cohort study of inpatient and emergency department settings.","volume":"68","author":"Miller","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi230256r52","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciz1038","article-title":"Changes in infective endocarditis admissions in Pennsylvania during the opioid epidemic.","volume":"71","author":"Meisner","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"zoi230256r53","doi-asserted-by":"publisher","first-page":"e2484","DOI":"10.1093\/cid\/ciaa1126","article-title":"Against medical advice discharges in injection and non-injection drug use-associated infective endocarditis: a nationwide cohort study.","volume":"73","author":"Kimmel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"zoi230256r54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258620","article-title":"Treatment-seeking behaviour among people with opioid use disorder in the high-income countries: a systematic review and meta-analysis.","volume":"16","author":"Hall","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"zoi230256r55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/add.v115.6","article-title":"Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis.","volume":"115","author":"Lewer","year":"2020","journal-title":"Addiction"},{"issue":"2","key":"zoi230256r56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jsat.2009.08.001","article-title":"Home- versus office-based buprenorphine inductions for opioid-dependent patients.","volume":"38","author":"Sohler","year":"2010","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi230256r57","first-page":"1","article-title":"United States life tables, 2008.","volume":"61","author":"Arias","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"zoi230256r58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2016.12.003","article-title":"Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan.","volume":"43","author":"Chang","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"5","key":"zoi230256r59","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/jac\/dkl087","article-title":"Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations.","volume":"57","author":"Verhagen","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"zoi230256r60","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.annepidem.2014.06.001","article-title":"Cause-specific mortality among people previously hospitalized with opioid-related conditions: a retrospective cohort study.","volume":"24","author":"Veldhuizen","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"7","key":"zoi230256r61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5220","article-title":"Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs.","volume":"1","author":"Rodger","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230256r62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cdt","article-title":"Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study.","volume":"7","author":"Cresti","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"zoi230256r63","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/eurheartj\/ehl427","article-title":"Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study.","volume":"28","author":"Hill","year":"2007","journal-title":"Eur Heart J"},{"issue":"7","key":"zoi230256r64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067519","article-title":"A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden.","volume":"8","author":"Ternhag","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"zoi230256r65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/PHH.0000000000000514","article-title":"Can emergency department, hospital discharge, and death data be used to monitor burden of drug overdose in Rhode Island?","volume":"23","author":"Jiang","year":"2017","journal-title":"J Public Health Manag Pract"},{"key":"zoi230256r67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jsat.2019.08.010","article-title":"Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City.","volume":"106","author":"Behrends","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi230256r70","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/add.v116.5","article-title":"Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial.","volume":"116","author":"Stein","year":"2021","journal-title":"Addiction"},{"issue":"22","key":"zoi230256r71","doi-asserted-by":"publisher","first-page":"625","DOI":"10.15585\/mmwr.mm6722a2","article-title":"Invasive methicillin-resistant staphylococcus aureus infections among persons who inject drugs\u2014six sites, 2005-2016.","volume":"67","author":"Jackson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi230256r72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","article-title":"A systematic review of injecting-related injury and disease among people who inject drugs.","volume":"171","author":"Larney","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"19","key":"zoi230256r73","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012969","article-title":"Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016.","volume":"8","author":"Kadri","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi230256r74","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12913-020-05670-z","article-title":"Engagement in primary health care among marginalized people who use drugs in Ottawa, Canada.","volume":"20","author":"Kendall","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"zoi230256r75","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2147\/NDT.S331442","article-title":"Factors that affect patient attrition in buprenorphine treatment for opioid use disorder: a retrospective real-world study using electronic health records.","volume":"17","author":"Ker","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"zoi230256r76","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102981","article-title":"Intersectional structural vulnerability to abusive policing among people who inject drugs: a mixed methods assessment in California\u2019s central valley.","volume":"87","author":"Friedman","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi230256r80","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11606-022-07456-x","article-title":"Trends in health service utilization after enrollment in an interdisciplinary primary care clinic for veterans with addiction, social determinants of health, or other vulnerabilities.","volume":"38","author":"Jones","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi230256r81","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s11606-018-4807-x","article-title":"Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization.","volume":"34","author":"Wakeman","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"8","key":"zoi230256r82","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1377\/hlthaff.2019.01559","article-title":"Primary care providers and specialists deliver comparable buprenorphine treatment quality.","volume":"39","author":"Gertner","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi230256r83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/08897077.2017.1363844","article-title":"Utilization of buprenorphine and methadone among opioid users who inject drugs.","volume":"39","author":"Tsui","year":"2018","journal-title":"Subst Abus"},{"key":"zoi230256r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108540","article-title":"Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.","volume":"133","author":"Morgan","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"zoi230256r85","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/acem.v29.8","article-title":"\u201cJust give them a choice\u201d: patients\u2019 perspectives on starting medications for opioid use disorder in the ED.","volume":"29","author":"Schoenfeld","year":"2022","journal-title":"Acad Emerg Med"},{"key":"zoi230256r86","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/QAI.0b013e3182097426","article-title":"The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine\/naloxone and HIV treatment.","volume":"56","author":"Weiss","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"zoi230256r87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12954-017-0196-4","article-title":"Harm reduction principles for healthcare settings.","volume":"14","author":"Hawk","year":"2017","journal-title":"Harm Reduct J"},{"issue":"6","key":"zoi230256r88","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.","volume":"27","author":"Schackman","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi230256r89","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse.","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi230256r90","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/08897077.2021.1903659","article-title":"It will end in tiers: a strategy to include \u201cdabblers\u201d in the buprenorphine workforce after the X-waiver.","volume":"42","author":"Saloner","year":"2021","journal-title":"Subst Abus"},{"issue":"4","key":"zoi230256r91","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/pop.2018.0163","article-title":"Integration of buprenorphine treatment with primary care: comparative effectiveness on retention, utilization, and cost.","volume":"22","author":"Hsu","year":"2019","journal-title":"Popul Health Manag"},{"issue":"1","key":"zoi230256r92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1940-0640-7-22","article-title":"Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.","volume":"7","author":"Rowe","year":"2012","journal-title":"Addict Sci Clin Pract"},{"key":"zoi230256r18","volume-title":"Cost Effectiveness in Health and Medicine","author":"Neumann","year":"2017","edition":"2nd ed"},{"key":"zoi230256r46","volume-title":"Drug Overdose Deaths in the United States, 1999\u20132017.","author":"Hedegaard","year":"2018"},{"key":"zoi230256r3","unstructured":"US Department of Health and Human Resources. Projecting the supply and demand for primary care practitioners through 2020. November 2013. Accessed January 20, 2022. https:\/\/bhw.hrsa.gov\/sites\/default\/files\/bureau-health-workforce\/data-research\/projecting-primary-care.pdf"},{"key":"zoi230256r16","unstructured":"Substance Abuse and Mental Health Services Administration. Harm Reduction. Accessed February 1, 2023. https:\/\/www.samhsa.gov\/find-help\/harm-reduction"},{"key":"zoi230256r17","unstructured":"ABIM Foundation. Surveys of Trust in the U.S. Health Care System. Accessed August 4, 2022. https:\/\/buildingtrust.org\/wp-content\/uploads\/2021\/05\/20210520_NORC_ABIM_Foundation_Trust-in-Healthcare_Part-1.pdf"},{"key":"zoi230256r26","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. US Dept of Health & Human Services; 2018. HHS publication (SMA) 18-5063FULLDOC. Accessed March 7, 2023. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf"},{"key":"zoi230256r31","unstructured":"Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among persons who inject drugs\u2014National HIV Behavioral Surveillance: injection drug use, 20 U.S. cities, 2015. HIV Surveillance Special Report 18. Revised edition. Published May 2018. Accessed January 1, 2020. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-special-report-number-24.pdf"},{"key":"zoi230256r32","unstructured":"US Census Bureau. Data from: Table DP05 - ACS Demographic and Housing Estimates. 2016. Accessed March 7, 2023. https:\/\/www.census.gov\/acs\/www\/data\/data-tables-and-tools\/data-profiles\/2016"},{"key":"zoi230256r40","unstructured":"Massachusetts Department of Public Health. Opioid-related EMS Transports Massachusetts Residents (2013\u20132015). Commonwealth of Massachusetts, Dept of Public Health; 2016. Accessed March 7, 2023. https:\/\/archives.lib.state.ma.us\/handle\/2452\/396531"},{"key":"zoi230256r41","unstructured":"Massachusetts Department of Public Health. Data Brief: Opioid-Related Overdose Deaths Among Massachusetts Residents. Vol 11. Commonwealth of Massachusetts, Dept of Public Health; 2019. Accessed March 7, 2023. https:\/\/www.mass.gov\/doc\/opioid-related-overdose-deaths-among-ma-residents-june-2020\/download"},{"key":"zoi230256r42","unstructured":"Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among persons who inject drugs\u2014national HIV behavioral surveillance: injection drug use, 20 U.S. cities, 2015. Accessed January 1, 2020. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html"},{"key":"zoi230256r47","unstructured":"Massachusetts Department of Public Health. An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011-2015). Commonwealth of Massachusetts, Dept of Public Health; 2017. Accessed March 7, 2023. https:\/\/www.mass.gov\/doc\/legislative-report-chapter-55-opioid-overdose-study-august-2017\/download"},{"key":"zoi230256r48","unstructured":"Massachusetts Department of Public Health. Data Brief: Opioid-Related Overdose Deaths among Massachusetts Residents. Commonwealth of Massachusetts, Dept of Public Health; 2019. Accessed March 7, 2023. https:\/\/archives.lib.state.ma.us\/bitstream\/handle\/2452\/802477\/ocn951537951-2019-05.pdf?sequence=1&isAllowed=y"},{"key":"zoi230256r66","unstructured":"Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Accessed January 20, 2022. https:\/\/www.meps.ahrq.gov\/mepsweb\/"},{"key":"zoi230256r68","unstructured":"US Department of Veterans Affairs. Pharmaceutical pricing: VA National Acquisition Center (NAC) programs. Accessed January 20, 2022. https:\/\/www.fss.va.gov\/index.asp"},{"key":"zoi230256r69","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule. Accessed January 20, 2022. https:\/\/www.cms.gov\/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files\/22clabq1"},{"key":"zoi230256r77","unstructured":"Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Accessed January 20, 2022. https:\/\/meps.ahrq.gov\/mepsweb"},{"key":"zoi230256r78","unstructured":"Process to Obtain Buprenorphine Waiver on DEA License. Accessed February 28, 2022. https:\/\/chcams.org\/wp-content\/uploads\/2018\/08\/DATA-2000-Waiver-Process.pdf"},{"key":"zoi230256r79","unstructured":"Bureau of Labor Statistics, US Department of Labor. Occupational Outlook Handbook, Physicians and Surgeons. Accessed August 8, 2022. https:\/\/www.bls.gov\/ooh\/healthcare\/physicians-and-surgeons.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803734\/jawa_2023_oi_230256_1683556138.07341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T15:04:45Z","timestamp":1683817485000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7888","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}